ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 30 for:    ocrelizumab

A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02720120
Recruitment Status : Terminated (The overall benefit risk profile of ocrelizumab was not favorable in RA)
First Posted : March 25, 2016
Last Update Posted : March 28, 2016
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study is in two parts and will evaluate the safety, tolerability and efficacy of escalating single intravenous (IV) doses of ocrelizumab compared with placebo in combination with methotrexate in participants with moderate to severe RA. Part 1 is the dose-escalation study, at one of the following dose levels of ocrelizumab [400, 1000, 1500, and 2000 milligrams (mg)]. In Part 2, participants will be randomized to explore tolerability and efficacy of doses which have been shown to be tolerated in Part 1.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: Ocrelizumab Drug: Placebo Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 175 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response
Study Start Date : October 2005
Actual Primary Completion Date : February 2013
Actual Study Completion Date : February 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Ocrelizumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Part 1: Ocrelizumab 1000 mg
Participants will receive single IV infusion of ocrelizumab 1000 mg.
Drug: Ocrelizumab
Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Other Name: RO4964913, rhuMAb 2H7, PRO70769
Experimental: Part 1: Ocrelizumab 1500 mg
Participants will receive single IV infusion of ocrelizumab 1500 mg.
Drug: Ocrelizumab
Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Other Name: RO4964913, rhuMAb 2H7, PRO70769
Experimental: Part 1: Ocrelizumab 2000 mg
Participants will receive single IV infusion of ocrelizumab 2000 mg.
Drug: Ocrelizumab
Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Other Name: RO4964913, rhuMAb 2H7, PRO70769
Experimental: Part 1: Ocrelizumab 400 mg
Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)
Drug: Ocrelizumab
Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Other Name: RO4964913, rhuMAb 2H7, PRO70769
Placebo Comparator: Part 1: Placebo
Participants will receive single IV infusion of placebo matched to ocrelizumab.
Drug: Placebo
Participants will receive single IV infusion of placebo.
Experimental: Part 2: Ocrelizumab 1000 mg
Participants will receive single IV infusion of ocrelizumab 1000 mg.
Drug: Ocrelizumab
Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Other Name: RO4964913, rhuMAb 2H7, PRO70769
Experimental: Part 2: Ocrelizumab 1500 mg
Participants will receive single IV infusion of ocrelizumab 1500 mg.
Drug: Ocrelizumab
Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Other Name: RO4964913, rhuMAb 2H7, PRO70769
Experimental: Part 2: Ocrelizumab 400 mg
Participants will receive single IV infusion of ocrelizumab 400 mg.
Drug: Ocrelizumab
Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Other Name: RO4964913, rhuMAb 2H7, PRO70769



Primary Outcome Measures :
  1. Percentage of Participants with Adverse Events (AEs) or Serious AEs (SAEs) [ Time Frame: Baseline up to approximately 7.25 years ]
  2. Percentage of Participants with Anti-Ocrelizumab Antibodies [ Time Frame: Baseline up to approximately 7.25 years ]

Secondary Outcome Measures :
  1. Percentage of Participants with American College of Rheumatology (ACR) 20%, 50%, and 70% (ACR20/50/70) Response at Week 24 [ Time Frame: Week 24 ]
  2. Disease Activity Score at Week 24 [ Time Frame: Week 24 ]
  3. Percentage of Participants achieving European League Against Rheumatism (EULAR) Response at Week 24 [ Time Frame: Week 24 ]
  4. Maximum Plasma Concentration (Cmax) of Ocrelizumab [ Time Frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24) ]
  5. Time to Blood B-Cell Depletion [ Time Frame: Baseline up to approximately 7.25 years ]
  6. Terminal Elimination Half-Life (t1/2) of Ocrelizumab [ Time Frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24) ]
  7. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity AUC(0-inf) of Ocrelizumab [ Time Frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24) ]
  8. Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration AUC(0-last) of Ocrelizumab [ Time Frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24) ]
  9. Time to Maximum Observed Plasma Concentration (Tmax) of Ocrelizumab [ Time Frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24) ]
  10. Terminal Rate Constant of Ocrelizumab [ Time Frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24) ]
  11. Systemic Clearance (CL) of Ocrelizumab [ Time Frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24) ]
  12. Mean Residence Time (MRT) of Ocrelizumab [ Time Frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24) ]
  13. Steady State Volume of Distribution (Vss) of Ocrelizumab [ Time Frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24) ]
  14. Duration of Blood B-Cell Depletion [ Time Frame: Baseline up to approximately 7.25 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Moderate to severe RA for at least 6 months
  • Positive serum rheumatoid factor (>/= 20 international units per milliliter)
  • Current treatment with RA on an outpatient basis
  • Treatment failure with one disease modifying anti-rheumatic drug (DMARD) or biologic, but have not failed more than six of these agents including methotrexate
  • Current treatment with methotrexate for at least 12 weeks, at a stable dose
  • Use of highly effective contraception.

Exclusion Criteria:

  • Rheumatic autoimmune disease or inflammatory joint disease, other than RA
  • Concurrent treatment with any disease-modifying anti-rheumatic drug (DMARD) (other than methotrexate) or any anti-tumor necrosis factor (TNF) -alfa or other biologic therapy
  • Treatment with any other investigational drug within 4 weeks of screening
  • Previous treatment with cell-depleting therapies, IV gamma-globulin, intra-articular or parenteral corticosteroids, and receipt of live/attenuated vaccine prior to screening
  • Previous treatment with rituximab or any other anti-cluster of differentiation 20 (CD20) agent
  • History of severe allergic or anaphylactic reactions to humanized monoclonal antibodies
  • Known active bacterial, viral or fungal infections
  • History of active tuberculosis and primary or secondary immunodeficiency
  • History of concomitant diseases such as cardiovascular disease, nervous system, pulmonary disease, renal, hepatic, endocrine or gastrointestinal disorders
  • Pregnancy or lactation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02720120


  Show 49 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02720120     History of Changes
Other Study ID Numbers: WA18230
2004-002132-26 ( EudraCT Number )
First Posted: March 25, 2016    Key Record Dates
Last Update Posted: March 28, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases